Morepen Laboratories Ltd vs Orchid Pharma Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Morepen Laboratories Ltd is ₹ 41.41 as of 30 Apr 15:30 . The P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 yearsThe P/E Ratio of Orchid Pharma Ltd changed from 33.9 on March 2023 to 39.5 on March 2025 . This represents a CAGR of 5.23% over 3 years The Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 yearsThe Market Cap of Orchid Pharma Ltd changed from ₹ 10061 crore on March 2021 to ₹ 3940 crore on March 2025 . This represents a CAGR of -17.10% over 5 years The revenue of Morepen Laboratories Ltd for the Dec '25 is ₹ 487.97 crore as compare to the Sep '25 revenue of ₹ 442.04 crore. This represent the growth of 10.39% The revenue of Orchid Pharma Ltd for the Dec '25 is ₹ 212.88 crore as compare to the Sep '25 revenue of ₹ 204.3 crore. This represent the growth of 4.2% The ebitda of Morepen Laboratories Ltd for the Dec '25 is ₹ 50.12 crore as compare to the Sep '25 ebitda of ₹ 61.16 crore. This represent the decline of -18.05% The ebitda of Orchid Pharma Ltd for the Dec '25 is ₹ 0.06 crore as compare to the Sep '25 ebitda of ₹ 9.3 crore. This represent the decline of -99.35% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 27.5 crore over 7 quarters. This represents a CAGR of -14.50% The net profit of Orchid Pharma Ltd changed from ₹ 28.27 crore to ₹ -12.15 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 yearsThe Dividend Payout of Orchid Pharma Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

About Orchid Pharma Ltd

Orchid Pharma Limited, is a vertically integrated pharmaceutical company with established research, manufacturing and marketing capabilities across multi-therapeutic domains.
Orchid's world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India.
The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai. The Company has a portfolio of antibiotics, and veterinary products.
Antibiotics are life-saving drugs used to ght infections.
Different classes of antibiotics include Beta-lactam, Macrolide, Fluoroquinolone, Imidazoleetc.

FAQs for the comparison of Morepen Laboratories Ltd and Orchid Pharma Ltd

Which company has a larger market capitalization, Morepen Laboratories Ltd or Orchid Pharma Ltd?

Market cap of Morepen Laboratories Ltd is 2,269 Cr while Market cap of Orchid Pharma Ltd is 3,187 Cr

What are the key factors driving the stock performance of Morepen Laboratories Ltd and Orchid Pharma Ltd?

The stock performance of Morepen Laboratories Ltd and Orchid Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Morepen Laboratories Ltd and Orchid Pharma Ltd?

As of May 4, 2026, the Morepen Laboratories Ltd stock price is INR ₹41.41. On the other hand, Orchid Pharma Ltd stock price is INR ₹628.5.

How do dividend payouts of Morepen Laboratories Ltd and Orchid Pharma Ltd compare?

To compare the dividend payouts of Morepen Laboratories Ltd and Orchid Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.